Linked Life Data

18026547

Source:http://linkedlifedata.com/resource/pubmed/id/18026547

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
33
pubmed:dateCreated
2007-11-20
pubmed:abstractText
A cost-effective optical cancer screening and monitoring technique was demonstrated in a pilot study of canine serum samples and was patented for commercialization. Compared to conventional blood chemistry analysis methods, more accurate estimations of the concentrations of albumin, globulins, and hemoglobin in serum were obtained by fitting the near UV absorbance and photoluminescence spectra of diluted serum as a linear combination of component reference spectra. Tracking these serum proteins over the course of treatment helped to monitor patient immune response to carcinoma and therapy. For cancer screening, 70% of dogs with clinical presentation of cancer displayed suppressed serum hemoglobin levels (below 20 mg/dL) in combination with atypical serum protein compositions, that is, albumin levels outside of a safe range (from 4 to 8 g/dL) and globulin levels above or below a more normal range (from 1.7 to 3.7 g/dL). Of the dogs that met these criteria, only 20% were given a false positive label by this cancer screening test.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0003-6935
pubmed:author
pubmed:issnType
Print
pubmed:day
20
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8080-8
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Canine cancer screening via ultraviolet absorbance and fluorescence spectroscopy of serum proteins.
pubmed:affiliation
Luna Innovations Incorporated, 3157 State Street, Blacksburg, Virginia 24060, USA.
pubmed:publicationType
Journal Article, Evaluation Studies